Clinical Study
Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy
Figure 2
Course of immunosuppression dosage and levels during TVR/PegIFN/RBV therapy.